New hair loss treatments in the pipeline: what is close and what is far

Every few weeks a new headline promises that the end of baldness is near. A cream from a lab in one country, an injection in another, a gene, a peptide, a stem cell. Some of these stories describe real medicines moving through real trials. Others describe a single experiment in mice, or a product that is being sold long before anyone knows whether it works.

This article sorts the current pipeline into four groups: what is already here, what is close, what is in early human trials, and what is still far away. It also gives you a short checklist for reading the next headline you see. It is general information, not personal medical advice.

Short answer

The newest approved hair loss medicines are JAK inhibitors for severe alopecia areata, such as baricitinib, ritlecitinib and deuruxolitinib ^{1 2 3}. For male pattern hair loss, the medicine closest to approval is clascoterone 5% solution, which completed phase 3 trials and reported positive six-month results in December 2025, but was not approved anywhere for hair loss at the time of writing ⁴. Several other medicines, such as the topical androgen receptor degrader GT20029, are in phase 2 ^{5 6}. Growing new follicles from cells is still at the laboratory stage ⁷.

For most people, the practical message is simple: proven treatments such as minoxidil and finasteride still do the heavy lifting, and waiting for a future medicine usually means losing hair that could have been kept.

How a medicine gets from the lab to your pharmacy

It helps to know the stages before looking at individual names.

• Laboratory and animal studies. A compound is tested on cells, hair follicles in a dish, or mice. Many ideas that work here never work in people.
• Phase 1. A small group of people, often healthy volunteers, receives the medicine to check safety and dosing.
• Phase 2. A few dozen to a few hundred patients are treated, usually against a placebo, to see whether the medicine seems to work and which dose is best.
• Phase 3. Hundreds or thousands of patients are treated in large controlled trials. These are the results regulators rely on most.
• Regulatory review. Agencies such as the Food and Drug Administration (FDA) in the United States, the European Medicines Agency or Malaysia's National Pharmaceutical Regulatory Agency review the data. Approval in one country does not mean approval in another.

Only a minority of medicines that enter phase 1 end up approved. So a medicine in phase 2 is interesting but far from certain, and a mouse study is a long way from a prescription.

Already here: what has changed in recent years

JAK inhibitors for alopecia areata

The biggest real change in hair loss treatment in the last few years has been for alopecia areata, an autoimmune condition in which the immune system attacks hair follicles. JAK inhibitors are oral medicines that calm part of this immune signalling.

• In the BRAVE-AA1 and BRAVE-AA2 trials, about 36–39% of adults with severe alopecia areata taking baricitinib 4 mg reached a scalp score of 20 or less (meaning at least about 80% scalp coverage) at week 36, compared with 3–6% on placebo ¹.
• In the ALLEGRO phase 2b/3 trial, 23% of patients on ritlecitinib 50 mg reached the same target at week 24 ².
• In the THRIVE-AA2 phase 3 trial of 517 patients, 33.0% on deuruxolitinib 8 mg twice daily and 38.3% on 12 mg twice daily reached the target at week 24, compared with 0.8% on placebo ³.

These are meaningful results for a condition that had few good options. But they come with important limits: they are for alopecia areata, not pattern hair loss; they need medical supervision and blood tests; and hair often falls out again if the medicine is stopped ⁸. For more detail, see JAK inhibitors for alopecia areata.

Low-dose oral minoxidil

Minoxidil tablets are not new, but their use for hair loss at low doses has grown a lot. Reviews and an international expert consensus now describe how doctors can use low-dose oral minoxidil for suitable patients ^{9 10}. A randomised trial in men found that 5 mg oral minoxidil was not clearly better than topical 5% minoxidil after 24 weeks, which is a reminder that new is not always better ¹¹. Read more in oral minoxidil for hair loss.

Topical finasteride

Finasteride in a scalp spray or solution is another adaptation of an older medicine, designed to reduce the amount reaching the bloodstream. Availability varies by country. See topical finasteride.

Close: completed phase 3, not yet approved

Clascoterone 5% solution

Clascoterone blocks the androgen receptor in the skin, the switch that DHT turns on in sensitive follicles. A 1% cream version is already approved in the United States for acne ¹². For hair loss, a stronger 5% scalp solution was tested in two phase 3 trials in men with moderate pattern hair loss ^{13 14}.

In December 2025 the developer announced that both trials met their main six-month goal for hair counts, with side effects similar to the placebo solution, and said it planned to file for approval after 12-month safety data were available ⁴. These results were released by press announcement and had not yet been published in a peer-reviewed journal at the time of writing. The trials included only men.

If it is approved, it would give men a hormone-targeting option that is applied to the scalp rather than swallowed. It is still something to watch, not something to buy. The full story is in clascoterone for hair loss.

In earlier trials: interesting, still uncertain

A 2026 review of emerging treatments for pattern hair loss lists several medicines in phase 1 or phase 2 trials ⁶. They fall into a few families.

Androgen receptor blockers and degraders

GT20029 is a topical medicine designed to break down the androgen receptor rather than just block it. In a phase 2 trial of 180 Chinese men over 12 weeks, two of the dosing groups had better hair counts than placebo, and side effects were similar between groups and mostly mild ⁵. Twelve weeks is short for hair loss, and the trial was modest in size, so larger and longer trials are needed. Pyrilutamide (KX-826), another topical androgen receptor blocker, has also been studied ¹⁵.

Prolactin receptor antibodies

Some researchers think the hormone prolactin plays a role in hair follicle cycling. Antibodies that block the prolactin receptor, such as HMI-115, are in early clinical development ⁶. This is a genuinely new idea, which also means there is a lot still unknown.

Follicle-cycle and metabolism approaches

Other candidates aim to push follicles back into the growth phase by acting on cell metabolism or signalling inside the follicle. The 2026 review mentions several such compounds, including PP405 and a topical thyroid-hormone-like molecule called KB-141, at early clinical stages ⁶. Researchers are also studying new forms of minoxidil, such as extended-release and sublingual versions ⁶.

What "early" really means

Medicines in phase 1 and 2 have been tested in tens to a few hundred people for weeks to months. That is enough to see a signal, not enough to know long-term safety or how well a medicine works in everyday life. Many such candidates never reach approval.

Being studied, not yet reliable: regenerative treatments

PRP, exosomes and stem cell products

Platelet-rich plasma is already offered in many clinics and has some supporting evidence, though studies vary a lot in method ¹⁶. Exosome and stem cell–derived products are newer. A 2026 review of regenerative options concluded that differences between studies and products make firm conclusions difficult, and that standardised trials are needed ¹⁵. The FDA in the United States has warned the public that no exosome products are approved ¹⁷. See exosome treatments and stem cell hair treatments.

Far away: growing new follicles

The idea of taking a few of your own cells and growing thousands of new hair follicles, sometimes called hair cloning, appears in the news regularly. Researchers are working on cell transplantation, reprogramming cells and growing follicle "organoids" in the lab. A 2025 review of this field described real progress but also major technical limitations, including keeping cells able to form hair, controlling where and how hair grows, and safety ⁷. This is laboratory and early research, not a treatment you can book.

Pipeline at a glance

How to read the next headline

When you see a story about a hair loss breakthrough, ask:

1. Was it in people? Results in mice or in a dish are a starting point, not an answer.
2. How many people, for how long? Hair grows slowly. A 12-week study of 30 people tells you much less than a 12-month study of 700.
3. Was there a placebo group? Hair counts can change with the seasons and with how photos are taken.
4. Is it peer reviewed? Press releases and conference talks are useful, but full publication allows scrutiny.
5. Are the numbers relative or absolute? "Five times better than placebo" can mean a small real difference.
6. Is it approved where you live? Approval in the United States, Europe or China does not automatically apply in Malaysia.
7. Is someone already selling it? If a product is on sale before trials are finished, be very cautious. See how to spot treatments with weak evidence.

Life in Malaysia

News of new treatments travels fast on social media in Malaysia, often in English, Malay and Chinese at once. A trial result from overseas can turn into a "new serum" on an online marketplace within days. These products usually have no connection to the medicine in the trial, and their contents are unknown.

Any new prescription medicine needs to be registered with Malaysia's drug regulator before it can be legally supplied here, and that can take time after approval elsewhere. Until then, the realistic options remain those a doctor can prescribe or recommend today, such as minoxidil, finasteride and, for suitable cases, procedures. Malaysia's heat and humidity also matter for daily-use topical products, as some people find solutions sticky or irritating in the climate.

Common myths

• "The end of baldness is coming next year." Medicines in late-stage trials can improve hair counts, but none of them is expected to reverse hair loss completely for everyone.
• "New means better." Some new formulations perform similarly to older ones. Proven, low-cost options are still the comparison point.
• "If it is in the news, it must be available." Many reported advances are in early trials or the laboratory.
• "JAK inhibitors work for all hair loss." They are studied and approved for alopecia areata, not for pattern hair loss.

Common mistakes

• Stopping a working treatment to wait for something new. Hair lost while waiting may not come back.
• Buying "trial" ingredients online. Products claiming to contain new medicines may contain something else or nothing useful.
• Paying for expensive unproven treatments because they sound advanced. Ask what evidence supports them.
• Ignoring the cause. New medicines target specific types of hair loss. Getting the right diagnosis comes first.

How a doctor assesses hair loss

A doctor will ask about your pattern of shedding, family history, health conditions, medicines and recent events such as illness or childbirth. They will examine your scalp, often with a dermatoscope, and may arrange blood tests if iron, thyroid or other causes are possible. This tells them whether you have pattern hair loss, alopecia areata, shedding from stress or illness, or another condition. Only then can they say whether a current treatment, a newer option, or a referral to a dermatologist makes sense. Taking regular photos also helps track whether any treatment is working.

Questions to ask your doctor

1. What type of hair loss do I have?
2. Which proven treatments suit me now?
3. Are any newer medicines relevant to my condition, and are they available in Malaysia?
4. If a new medicine becomes available, would it replace or add to what I am using?
5. What side effects should I watch for with my current treatment?
6. How long should I try a treatment before judging it?
7. Is this product or clinic treatment I saw online backed by good evidence?
8. Would I benefit from seeing a dermatologist?

Bottom line

There is real progress in hair loss research. JAK inhibitors have changed the outlook for severe alopecia areata, and clascoterone may become a new option for men with pattern hair loss in the coming years. Other medicines are earlier in the pipeline, and follicle cloning remains in the lab. None of this changes the best step for most people today: get a diagnosis and start a proven treatment early. For an overview of current options, see the guide to hair loss treatment in Malaysia.

Frequently asked questions

Are there any new hair loss treatments in 2026?

The newest approved medicines are JAK inhibitors for severe alopecia areata. For pattern hair loss, clascoterone solution has completed phase 3 trials in men but was not approved at the time of writing, and several other medicines are in earlier trials.

What is closest to approval for male pattern hair loss?

Clascoterone 5% solution, a topical androgen receptor blocker. Its developer reported positive six-month phase 3 results in December 2025 and planned regulatory submissions after 12-month safety data.

What are JAK inhibitors?

They are oral medicines that calm the immune attack on hair follicles in alopecia areata. Baricitinib, ritlecitinib and deuruxolitinib have shown benefit in phase 3 trials for severe alopecia areata. They are not treatments for pattern hair loss.

Is hair cloning or growing new follicles available?

No. Growing new hair follicles from cells is still at the laboratory and animal research stage, and there are major technical hurdles before it could be tested widely in people.

How long does it take a new medicine to reach patients?

Usually many years. After phase 3 trials, regulators review the data, and approval in one country does not mean approval in Malaysia. Many promising medicines fail along the way.

Should I wait for new treatments instead of starting now?

Pattern hair loss tends to progress, and current treatments work best when started early. A doctor can help you start a proven option now and review new options as they become available.

Are exosomes and stem cell treatments new breakthroughs?

They are being studied, but evidence is early and products vary widely. Reviews call for larger, standardised trials before they can be relied on.

How can I judge a news headline about a hair loss breakthrough?

Check whether the study was in people, how many took part, whether there was a placebo group, whether results are peer reviewed, and whether the medicine is approved where you live.

Educational content. Not medical advice.